Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase  3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)

ConclusionRoxadustat was non-inferior to ESAs in maintaining hemoglobin levels in this cohort of patients with anemia of CKD on dialysis for at least 4  months who were previously treated with ESAs. Observed TEAEs were consistent with previous studies.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research